(22UA) BioNTech SE - Ratings and Ratios
Cancer Vaccines, mRNA Therapies, Checkpoint Inhibitors, CAR-T Programs
EPS (Earnings per Share)
Revenue
| Risk via 10d forecast | |
|---|---|
| Volatility | 48.3% |
| Value at Risk 5%th | 59.8% |
| Relative Tail Risk | -24.66% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.36 |
| Alpha | -19.00 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.303 |
| Beta | 0.350 |
| Beta Downside | 0.221 |
| Drawdowns 3y | |
|---|---|
| Max DD | 58.95% |
| Mean DD | 43.56% |
| Median DD | 45.58% |
Description: 22UA BioNTech SE October 16, 2025
BioNTech SE (XETRA: 22UA) is a German biotechnology firm focused on developing and commercializing mRNA-based immunotherapies for cancer and infectious diseases. Founded in 2008 and headquartered in Mainz, the company leverages its proprietary mRNA platform to generate a broad pipeline of therapeutic candidates.
The current pipeline spans more than 20 programs, including BNT111 (Phase 2 melanoma), BNT113 (Phase 2 head-and-neck squamous cell carcinoma), BNT116 (Phase 1 non-small cell lung cancer), and the multi-indication candidate BNT122/RO7198457 (Phase 2 adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal, pancreatic, and advanced melanoma). Late-stage assets such as BNT311/GEN1046 (ac-asunlimab) are in Phase 3 for solid tumors, while BNT327 and BNT316/ONC-392 are progressing through Phase 1-3 trials across several solid-tumor indications, reflecting a diversified clinical portfolio.
Key financial metrics as of FY 2023 show revenue of €4.6 billion, driven primarily by the COVID-19 mRNA vaccine partnership with Pfizer, and a cash-and-cash-equivalents balance of roughly €5.5 billion, providing ample runway for R&D spend that topped €2 billion. The company’s R&D intensity (~43% of revenue) underscores its commitment to expanding the pipeline beyond the vaccine franchise.
Sector-wide, the biotechnology industry is benefitting from accelerating adoption of mRNA technology, heightened investor appetite for precision oncology, and supportive regulatory pathways for accelerated approvals. However, valuation sensitivity remains high to trial outcomes and competitive pressures from other mRNA-focused firms.
For a deeper, data-driven valuation of BioNTech’s pipeline risk-adjusted upside, the ValueRay platform offers a granular analyst-grade model worth exploring.
22UA Stock Overview
| Market Cap in USD | 25,059m |
| Sub-Industry | Biotechnology |
| IPO / Inception | |
| Return 12m vs S&P 500 | -20.2% |
| Analyst Rating | - |
22UA Dividends
Currently no dividends paid22UA Growth Ratios
| Metric | Value |
|---|---|
| CAGR 3y | -19.56% |
| CAGR/Max DD Calmar Ratio | -0.33 |
| CAGR/Mean DD Pain Ratio | -0.45 |
| Current Volume | 34.3k |
| Average Volume | 29.4k |
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income (-571.6m TTM) > 0 and > 6% of Revenue (6% = 189.2m TTM) |
| FCFTA -0.05 (>2.0%) and ΔFCFTA -9.46pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 431.7% (prev 525.1%; Δ -93.44pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.02 (>3.0%) and CFO 354.2m > Net Income -571.6m (YES >=105%, WARN >=100%) |
| Net Debt (-9.85b) to EBITDA (173.3m) ratio: -56.82 <= 3.0 (WARN <= 3.5) |
| Current Ratio 7.12 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (240.5m) change vs 12m ago 0.30% (target <= -2.0% for YES) |
| Gross Margin 83.20% (prev 86.53%; Δ -3.32pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 14.41% (prev 13.57%; Δ 0.84pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -4.14 (EBITDA TTM 173.3m / Interest Expense TTM 50.8m) >= 6 (WARN >= 3) |
Altman Z'' 13.61
| (A) 0.64 = (Total Current Assets 15.83b - Total Current Liabilities 2.22b) / Total Assets 21.34b |
| (B) 0.86 = Retained Earnings (Balance) 18.27b / Total Assets 21.34b |
| warn (B) unusual magnitude: 0.86 — check mapping/units |
| (C) -0.01 = EBIT TTM -210.1m / Avg Total Assets 21.87b |
| (D) 6.38 = Book Value of Equity 18.27b / Total Liabilities 2.86b |
| Total Rating: 13.61 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 21.65
| 1. Piotroski 1.0pt |
| 2. FCF Yield -9.29% |
| 3. FCF Margin -34.73% |
| 4. Debt/Equity 0.01 |
| 5. Debt/Ebitda -56.82 |
| 6. ROIC - WACC (= -9.55)% |
| 7. RoE -3.04% |
| 8. Rev. Trend -26.77% |
| 9. EPS Trend -55.19% |
What is the price of 22UA shares?
Over the past week, the price has changed by -3.43%, over one month by -5.12%, over three months by -8.17% and over the past year by -10.71%.
Is 22UA a buy, sell or hold?
What are the forecasts/targets for the 22UA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 78.4 | -10.1% |
22UA Fundamental Data Overview November 18, 2025
Market Cap EUR = 21.63b (21.63b EUR * 1.0 EUR.EUR)
P/E Forward = 7.1429
P/S = 6.8609
P/B = 1.1706
P/EG = 0.0464
Beta = 1.308
Revenue TTM = 3.15b EUR
EBIT TTM = -210.1m EUR
EBITDA TTM = 173.3m EUR
Long Term Debt = 192.0m EUR (from longTermDebt, last quarter)
Short Term Debt = 53.4m EUR (from shortLongTermDebt, last quarter)
Debt = 245.4m EUR (Calculated: Short Term 53.4m + Long Term 192.0m)
Net Debt = -9.85b EUR (calculated as Total Debt 245.4m - CCE 10.09b)
Enterprise Value = 11.78b EUR (21.63b + Debt 245.4m - CCE 10.09b)
Interest Coverage Ratio = -4.14 (Ebit TTM -210.1m / Interest Expense TTM 50.8m)
FCF Yield = -9.29% (FCF TTM -1.09b / Enterprise Value 11.78b)
FCF Margin = -34.73% (FCF TTM -1.09b / Revenue TTM 3.15b)
Net Margin = -18.13% (Net Income TTM -571.6m / Revenue TTM 3.15b)
Gross Margin = 83.20% ((Revenue TTM 3.15b - Cost of Revenue TTM 529.5m) / Revenue TTM)
Gross Margin QoQ = 90.24% (prev 70.71%)
Tobins Q-Ratio = 0.55 (Enterprise Value 11.78b / Total Assets 21.34b)
Interest Expense / Debt = 1.39% (Interest Expense 3.40m / Debt 245.4m)
Taxrate = 216.2% (out of range, set to none) (53.4m / 24.7m)
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = 7.12 (Total Current Assets 15.83b / Total Current Liabilities 2.22b)
Debt / Equity = 0.01 (Debt 245.4m / totalStockholderEquity, last quarter 18.48b)
Debt / EBITDA = -56.82 (Net Debt -9.85b / EBITDA 173.3m)
Debt / FCF = 8.99 (negative FCF - burning cash) (Net Debt -9.85b / FCF TTM -1.09b)
Total Stockholder Equity = 18.83b (last 4 quarters mean from totalStockholderEquity)
RoA = -2.68% (Net Income -571.6m / Total Assets 21.34b)
RoE = -3.04% (Net Income TTM -571.6m / Total Stockholder Equity 18.83b)
RoCE = -1.10% (EBIT -210.1m / Capital Employed (Equity 18.83b + L.T.Debt 192.0m))
RoIC = -2.33% (negative operating profit) (EBIT -210.1m / (Assets 21.34b - Curr.Liab 2.22b - Cash 10.09b))
WACC = 7.22% (E(21.63b)/V(21.87b) * Re(7.30%) + (debt cost/tax rate unavailable))
Discount Rate = 7.30% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: 100.0 | Cagr: 0.57%
Fair Price DCF = unknown (Cash Flow -1.09b)
EPS Correlation: -55.19 | EPS CAGR: -38.10% | SUE: -0.16 | # QB: 0
Revenue Correlation: -26.77 | Revenue CAGR: -31.38% | SUE: N/A | # QB: 0